Skip to search formSkip to main contentSkip to account menu

bendamustine hydrochloride

Known as: Bendamustine Hydrochloride [Chemical/Ingredient], 2-Benzimidazolinebutryric acid, 1-methyl-5-bis(2-chloroethyl)amino-, hydrochloride, Bendamustin Hydrochloride 
The hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine… 
National Institutes of Health

Related topics

Related topics

18 relations

Broader (1)

Antineoplastic Agents, Alkylating

Narrower (6)

CytostasanRibomustinSDX-105SyB L-0501
In BloodNCIt Antineoplastic Agent Terminologyagonistsanalogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Bendamustine–rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy
2017
2017
Bendamustine-PAMAM Conjugates for Improved Apoptosis, Efficacy, and in Vivo Pharmacokinetics: A Sustainable Delivery Tactic.
Successful delivery of a chemotherapeutic agent like bendamustine still remains a challenge in clinical conditions like chronic… 
2016
2016
Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study
Background: Minimal residual disease (MRD) status reflects treatment efficacy and may predict prognosis after first-line therapy… 
2015
2015
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology…
2015
2015
Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma
The aim of the present study was to investigate the feasibility of measuring metabolic tumor burden using [F‐18… 
2012
2012
Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma.
Review
2011
Review
2011
Chronic lymphocytic leukemia in less fit patients: “slow-go”
Abstract The management of “slow-go” patients with chronic lymphocytic leukemia (CLL) remains a primary unmet clinical need. This… 
2010
2010
Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Abstract 3904 Background: Navitoclax (ABT-263), a novel, orally bioavailable, small molecule, binds with high affinity (Ki ≤1nM… 
2009
2009
Identification and Quantitation of the N-Acetyl-L-cysteine S-Conjugates of Bendamustine and Its Sulfoxides in Human Bile after Administration of Bendamustine Hydrochloride
We recently reported the detection of mercapturic acid pathway metabolites of bendamustine, namely, cysteine S-conjugates in… 
2007
2007
Bendamustine hydrochloride in patients with refractory soft tissue sarcoma
For patients with advanced soft tissue sarcoma (STS), no standard treatment is established after previous chemotherapy with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)